---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-136095"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:31:50.969674+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BridgeBio enters $450M ATM equity offering program; terminates prior $500M facility

## Summary
- ATM allows sale of up to $450M in common stock at Company's discretion; 3% commission to agents.
- Prior ATM with Jefferies and SVB Securities terminated effective May 3, 2023.
- Goldman Sachs and SVB Securities serve as sales agents on a best-efforts basis.
- Shares may be sold as 'at the market' offerings on Nasdaq or other trading markets.

## SEC filing metadata
- accession: 0001193125-23-136095
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000119312523136095/0001193125-23-136095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000119312523136095/d336282d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-136095
- JSON: https://secwatch.observer/filing/0001193125-23-136095.json
- Plain text: https://secwatch.observer/filing/0001193125-23-136095.txt

## Key facts
- Material Agreements
  BridgeBio Pharma, Inc. entered into Equity Distribution Agreement with Goldman Sachs & Co. LLC and SVB Securities LLC valued at up to $450,000,000 (effective 2023-05-04).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Goldman Sachs & Co. LLC and SVB Securities LLC
  - Value: up to $450,000,000
  - Effective: 2023-05-04
  source text: On May 4, 2023, the Company entered into an Equity Distribution Agreement (the “Agreement”) with Goldman Sachs & Co. LLC and SVB Securities LLC (the “Sales Agents”) with respect to an “at-the-market” offering program under which the Company may issue and sell, from time to time at its sole discretion and pursuant to a prospectus supplement, shares of its common stock, par value $0.001 per share (“Common Stock”), having an aggregate offering price of up to $450,000,000 (the “Placement Shares”), through the Sales Agents.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000119312523136095/0001193125-23-136095-index.htm
- Material Agreements
  BridgeBio Pharma, Inc. terminated Open Market Sales Agreement with Jefferies LLC and SVB Securities LLC (effective 2023-05-03).
  - Action: termination
  - Agreement: atm program
  - Counterparty: Jefferies LLC and SVB Securities LLC
  - Effective: 2023-05-03
  source text: On May 3, 2023, Jefferies LLC (“Jefferies”) and SVB Securities LLC (formerly known as SVB Leerink LLC, “SVB Securities”), acknowledged and accepted the Company’s prior written notice to terminate the Open Market Sales Agreement SM , dated July 7, 2020, by and among the Company, Jefferies and SVB Securities, for convenience, effective as of May 3, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000119312523136095/0001193125-23-136095-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.